ORIGINAL RESEARCH article
Front. Public Health
Sec. Digital Public Health
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1574116
Scaling up of electronic case-based disease surveillance reporting for COVID-19 and other notifiable diseases through capacity building and antigen RDT provision: A case study of
Provisionally accepted- 1Ministry of Health, Freetown, Sierra Leone
- 2World Health Organization, Freetown, Sierra Leone
- 3District Health Management Team, Western Area Urban, Sierra Leone
- 4African Field Epidemiology Network, Freetown, Sierra Leone
- 5World Health Organization - Regional Office for Africa, Brazzaville, Republic of Congo
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Electronic case-based disease surveillance (eCBDS) provides timely and detailed data collection on diseases and their risk factors for control actions. Use of eCBDS is still low in many African countries including Sierra Leone due to technological, financial, and human resource challenges. Sierra Leone started using eCBDS in 2019 and the COVID-19 pandemic provided the right opportunity for scale up. To support the scale up, a capacity building project was carried out on use of eCBDS for COVID-19 reporting as well as use of COVID-19 antigen rapid diagnostic kits (RDTs). This paper describes how the capacity building was conducted and the outcomes.This was a descriptive study where 607 health workers from 155 health facilities in 16 districts were trained on COVID-19 case-based reporting and RDTs use. The training was conducted in phases from November 2021 to June 2022 and post-training monitoring for impact was done up to May 2024. Data collection was done mainly through the eCBDS system where quantitative data was downloaded and analyzed for response timelines. Qualitative data was collected from key informants from selected health facilities using a semi-structured questionnaire.The number of health facilities that had ever reported a case of a notifiable disease through the eCBDS in the country was 385/1423 (27%) as of 30 th June 2021 (before training) and this increased to 58% as of 30 th May 2024 (endline). The total number of cases (all diseases) reported in eCBDS from January 2019 to 30 th May 2024 was 54,794. Of the reported cases, 44,908 (82%) were suspected COVID-19 cases of which 7,634 (17%) were confirmed positive. Before the training, 97.3% of suspected COVID-19 cases were notified to the district by the health facilities within 24 hours, and this improved slightly to 98.1% afterwards. Case investigation with sample collection within 24 hours of notification improved from 91.6% to 98.2% before and after the training, respectively.The COVID-19 pandemic provided a unique opportunity for the country to scale up eCBDS in more health facilities, and this improved notification and investigation timelines. However, more still needs to be done to ensure countrywide use of eCBDS.
Keywords: electronic, Case-Based, disease surveillance, COVID-19, Sierra Leone
Received: 10 Feb 2025; Accepted: 28 Apr 2025.
Copyright: © 2025 Squire, Njeru, Musoke, Kanu, Bangura, Koroma, Harding, Sesay, Magoba, Bashir, Caulker, Vandi, Nuwagira and Njuguna. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ian Njeru, World Health Organization, Freetown, Sierra Leone
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.